The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha.

The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Abstract Text:

Cheng-Jun Hu,Aneesa Sataur,Liyi Wang,Hongqing Chen,M Celeste Simon,Cheng-Jun Hu,Aneesa Sataur,Liyi Wang,Hongqing Chen,M Celeste Simon,

The basic helix-loop-helix-Per-ARNT-Sim-proteins hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha are the principal regulators of the hypoxic transcriptional response. Although highly related, they can activate distinct target genes. In this study, the protein domain and molecular mechanism important for HIF target gene specificity are determined. We demonstrate that although HIF-2alpha is unable to activate multiple endogenous HIF-1alpha-specific target genes (e.g., glycolytic enzymes), HIF-2alpha still binds to their promoters in vivo and activates reporter genes derived from such targets. In addition, comparative analysis of the N-terminal DNA binding and dimerization domains of HIF-1alpha and HIF-2alpha does not reveal any significant differences between the two proteins. Importantly, replacement of the N-terminal transactivation domain (N-TAD) (but not the DNA binding domain, dimerization domain, or C-terminal transactivation domain [C-TAD]) of HIF-2alpha with the analogous region of HIF-1alpha is sufficient to convert HIF-2alpha into a protein with HIF-1alpha functional specificity. Nevertheless, both the N-TAD and C-TAD are important for optimal HIF transcriptional activity. Additional experiments indicate that the ETS transcription factor ELK is required for HIF-2alpha to activate specific target genes such as Cited-2, EPO, and PAI-1. These results demonstrate that the HIF-alpha TADs, particularly the N-TADs, confer HIF target gene specificity, by interacting with additional transcriptional cofactors.

The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Publishing Authors By Initials

CJ Hu,A Sataur,L Wang,H Chen,MC Simon,CJ Hu,A Sataur,L Wang,H Chen,MC Simon,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Molecular biology of the cell

VOLUME: 18

Page Numbers: 4528-42

Journal Abbreviation: Mol. Biol. Cell

ISSN: 1059-1524

DAY: 5

MONTH: 09

YEAR: 2007

The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9201390

The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha.

AFFILIATION: Abramson Family Cancer Research Institute,University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

Country: United States

AGENCY: United States PHS

GRANT: 66130

ACRONYM:

MEDLINETA: Mol Biol Cell

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha Related Publications

• Acidotoxicity trumps excitotoxicity in ischemic brain.
• Acute postnatal ablation of Hif-2alpha results in anemia.
• Azetidinones as vasopressin V1a antagonists.
• Binding of warfarin influences the acid-base equilibrium of H242 in sudlow site I of human serum albumin.
• CNS lymphoma in an AIDS patient involving the posterior fornix case report.
• Changes in osmolality sensitize the response to capsaicin in trigeminal sensory neurons.
• Chronic ethanol consumption increases dopamine uptake in the nucleus accumbens of high alcohol drinking rats.
• Concurrent encoding of frequency and amplitude modulation in human auditory cortex: MEG evidence.
• Differential regulation of Tbx5 protein expression and sub-cellular localization during heart development.
• Dynamics of clathrin and adaptor proteins during endocytosis.
• Educational Corner: Inhibition of eosinophil apoptosis in chronic allergic disease.
• Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
• Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
• Gustatory Effects of Capsaicin that are Independent of TRPV1 Receptors.
• Hepatitis viruses in non-human primates.
• Human endometrial mucin MUC1 is up-regulated by progesterone and down-regulated in vitro by the human blastocyst.
• Human standing and walking: comparison of the effects of stimulation of the vestibular system.
• Imaging single events at the cell membrane.
• Improving the filter between primary and secondary care for mental disorders.
• Mechanistic studies on the photochemical deprotection of 3',5'-dimethoxybenzoin esters.
• Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro.
• Novel therapeutic strategies via the apoptosis pathways to resolve chronic eosinophilic inflammation.
• On call: I am a 71-year-old man with diabetes and high blood pressure. Ever since I can remember, I've been bothered by painful canker sores two or three times a year. My doctor says they aren't caused by my medication and I think he's right, since the ca
• Optical monitoring of single cells using quantum dots.
• Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix.
• Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis.
• Recirculation of inhaled xenon does not alter lung CT density.
• Strong calcium phosphate cement-chitosan-mesh construct containing cell-encapsulating hydrogel beads for bone tissue engineering.
• The transcriptional repressor GFI-1 antagonizes PU.1 activity through protein-protein interaction.
• Vascular mimetics based on microfluidics for imaging the leukocyte--endothelial inflammatory response.